A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia

Authors:

Abstract
T‐cell acute lymphoblastic leukemia (T‐ALL) is a highly aggressive hematological malignancy for which targeted therapies remain underdeveloped. Oncogenic mutations in Notch1 occur in up to 75% of T‐ALL patients. Although γ‐secretase inhibitors (GSIs) can block Notch1 activation, their clinical application is limited by side effects and reduced sensitivity. Here, a self‐assembling, reactive oxygen species (ROS)‐responsive nanotherapeutic strategy—PHD/G‐NPs—co‐loaded with GSI and controlled released dihydroartemisinin (DHA), and modified with a CD38 antibody is reported. The CD38 antibody specifically targets T‐ALL cells, while GSI selectively inhibits Notch1, resulting in a dual‐targeting approach. GSI is released first, inhibiting Notch1 activation and inducing the death of a subset of T‐ALL cells. To eliminate semi‐quiescent T‐ALL cells that escape initial therapy by elevating ROS levels, a ROS‐sensitive DHA delivery system is employed to enhance ferroptosis and boost GSI efficacy. After elucidating the mechanism of action of PHD/G‐NPs in T‐ALL cells, PHD/G‐NPs are combined with αPD‐1, which triggers an anti‐tumor immune response in vivo. This dual‐targeting strategy using CD38‐modified PHD/G‐NPs enables controlled drug release, enhances ferroptosis, mitigates GSI‐induced gastrointestinal toxicity, and improves therapeutic efficacy. This nanomedical approach offers a novel strategy for targeted T‐ALL treatment.
Funding Information
  • National Natural Science Foundation of China (82070160, 82170182, 82370165, 82470153, 82470163, 82473859)
  • Natural Science Foundation of Shandong Province (ZR2023MH228, ZR2023YQ065, ZR2024QH600, ZR202111140029)
  • China Postdoctoral Science Foundation (2023M742111)
  • Fundamental Research Funds for the Central Universities (2022JC012)

This publication has 36 references indexed in Scilit: